Blocking LAG-3 has been demonstrated to improve cytotoxic T-lymphocyte proliferation, and for this study, a tolerable response was observed as a monotherapy and in combination with anti-PD-1 spartalizumab [119], highlighting the importance of inhibitor of immune checkpoint therapies in metastatic cancers. The gene discussed is LAG3; the disease is metastatic malignant neoplasm.